Tatiana Cattaruzza
Overview
Explore the profile of Tatiana Cattaruzza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ilardi C, Menichelli A, Michelutti M, Cattaruzza T, Federico G, Salvatore M, et al.
J Alzheimers Dis
. 2024 Aug;
101(1):293-308.
PMID: 39150828
Background: In the era of disease-modifying therapies, empowering the clinical neuropsychologist's toolkit for timely identification of mild cognitive impairment (MCI) is crucial. Objective: Here we examine the clinimetric properties of...
2.
Ilardi C, Menichelli A, Michelutti M, Cattaruzza T, Manganotti P
Neurol Sci
. 2022 Sep;
44(1):159-170.
PMID: 36169756
Objective: In this phase II psychometric study on the Montreal cognitive assessment (MoCA), we tested the clinicometric properties of Italian norms for patients with mild cognitive impairment (PwMCI) and early...
3.
Florean I, Penolazzi B, Menichelli A, Pastore M, Cattaruzza T, Mazzon G, et al.
J Clin Exp Neuropsychol
. 2022 Feb;
43(9):926-943.
PMID: 35166171
Introduction: Many studies have attempted to determine whether Alzheimer's disease (AD) in-vivo biomarkers can predict neuropsychological performance since pathophysiological changes precede cognitive changes by several years. Nonetheless, neuropsychological measures can...
4.
Perra D, Bongianni M, Novi G, Janes F, Bessi V, Capaldi S, et al.
Brain Commun
. 2021 Apr;
3(2):fcab045.
PMID: 33870192
In patients with suspected dementia with Lewy bodies, the detection of the disease-associated α-synuclein in easily accessible tissues amenable to be collected using minimally invasive procedures remains a major diagnostic...
5.
Vignando M, Rumiati R, Manganotti P, Cattaruzza T, Aiello M
J Neuropsychol
. 2019 Oct;
14(3):431-448.
PMID: 31617330
The hypothesis that semantic deficits in dementia may contribute in producing changes in eating preferences has never been experimentally investigated despite this association has been clinically observed. We administered tasks...
6.
Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, Cagnin A, et al.
Ann Clin Transl Neurol
. 2019 Oct;
6(10):2120-2126.
PMID: 31599499
We applied RT-QuIC assay to detect α-synuclein aggregates in cerebrospinal fluid (CSF) of patients with suspected Creutzfeldt-Jakob disease who had a neuropathological diagnosis of dementia with Lewy bodies (DLB) (n ...
7.
Mazzon G, Ajcevic M, Cattaruzza T, Menichelli A, Guerriero M, Capitanio S, et al.
Curr Alzheimer Res
. 2019 May;
16(6):483-494.
PMID: 31057108
Background: Diagnosis of prodromal Alzheimer's disease (AD) still represents a hot topic and there is a growing interest for the detection of early and non-invasive biomarkers. Although progressive episodic memory...
8.
Mazzon G, Menichelli A, Fabretto A, Cattaruzza T, Manganotti P
Neurocase
. 2018 Jul;
24(3):140-144.
PMID: 29969053
Speech apraxia is a disorder of speech motor planning/programming leading to slow rate, articulatory distortion, and distorted sound substitutions. We describe the clinical profile evolution of a patient presenting with...
9.
Mazzon G, De Dea F, Cattaruzza T, Manganotti P, Monti F, Accardo A
Curr Alzheimer Res
. 2018 Apr;
15(9):809-819.
PMID: 29701152
Background: Mild (MCI) and Subjective Cognitive Impairment (SCI) are conditions at risk of developing Alzheimer's disease (AD). Differential between normal aging at early stages can be really challenging; available biomarkers...
10.
Bongianni M, Orru C, Groveman B, Sacchetto L, Fiorini M, Tonoli G, et al.
JAMA Neurol
. 2016 Dec;
74(2):155-162.
PMID: 27942718
Importance: Early and accurate in vivo diagnosis of Creutzfeldt-Jakob disease (CJD) is necessary for quickly distinguishing treatable from untreatable rapidly progressive dementias and for future therapeutic trials. This early diagnosis...